New drug could keep rare blood disease in check
NCT ID NCT06831058
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests efgartigimod, a drug that lowers harmful antibodies, in 15 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare and life-threatening blood disorder. Participants receive weekly infusions for 8 weeks, then are monitored for another 8 weeks. The goal is to see if the drug can safely raise ADAMTS13 activity and prevent relapses better than the current standard, rituximab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- efgartigimod
- What this could lead to
- If it works, this could point toward a safer maintenance therapy to prevent relapses of iTTP without long-term immune suppression.
- What could go wrong
- This is a very small pilot study (15 people) comparing results to past patients, not a controlled trial. The effect may be temporary, and the drug may not prevent relapses better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.